UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January 10, 2007
CALIPER LIFE SCIENCES, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware | | 0-28229 | | 33-0675808 |
(State or other jurisdiction of | | (Commission | | (IRS Employer |
incorporation) | | File Number) | | Identification No.) |
| | | | |
68 Elm Street, Hopkinton, Massachusetts | | 01748 |
(Address of Principal Executive Offices) | | (Zip Code) |
(508) 435-9500
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 2.02. Results of Operations and Financial Condition.
On January 10, 2007, Caliper Life Sciences, Inc., a Delaware corporation (“Caliper”), issued a press release announcing that later that same day Kevin Hrusovsky, President and Chief Executive Officer of Caliper, will present at the JP Morgan 25th Annual Healthcare Conference in San Francisco, during which he will discuss, among other things, Caliper’s expectations regarding its 2006 top-level financial performance and year-end cash position. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.
The information in this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Caliper, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
ITEM 9.01. Financial Statements and Exhibits.
Exhibit No. | | Exhibit |
| | |
99.1 | | Press Release entitled “Caliper Life Sciences to Present at JP Morgan 25th Annual Healthcare Conference Today” dated January 10, 2007 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Caliper Life Sciences, Inc. |
| |
| |
Date: January 10, 2007 | By: | /s/ Thomas T. Higgins |
| | Thomas T. Higgins |
| | Executive Vice President & Chief Financial Officer |
3
